Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly and Company’s LLY shares have lost 8.2% in the past month. A lot of this price decline is due to the global ...

A meta-analysis of recent studies found a global steatotic liver disease prevalence of 37.5%. ( Clinical Gastroenterology and ...

Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their GLP-1 products. Lilly markets its dual GIP and GLP-1 receptor agonist, ...

The UC space is highly diversified with a number of molecules approved. In October 2023, the FDA approved Omvoh (mirikizumab), an interleukin-23 antagonist developed by Eli Lilly. It is indicated ...

This significant milestone makes Tremfya the latest addition to the IL-23 class in Crohn’s, joining AbbVie’s Skyrizi (risankizumab) and Eli Lilly’s Omvoh (mirikizumab), all now available for ...

Other significant developments include promising phase 3 trial results for alopecia areata and the FDA's approval of Omvoh, which, along with solid earnings, position the company favorably even as ...

The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with moderately to severely active Crohn disease. This approval is the fourth ...

along with approval for Omvoh for managing moderately to severely active Crohn’s disease. Eli Lilly and Company (NYSE:LLY), one of the best dividend zombies, has been paying dividends to ...

Other IL-23 inhibitors approved for Crohn's disease include risankizumab (Skyrizi) and mirikizumab (Omvoh). Common adverse events (≥3%) with guselkumab in the Crohn's disease trials included ...